Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1799 results
June 2020
-
Key ReleaseNovartis Resolves Legacy FCPA InvestigationsBasel, June 25, 2020 – Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA)…
-
Media ReleaseNovartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosisThe Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) was initiated in 2019 as part of a commitment to innovation in Neuroscience to identify and encourage technology ideas from…
-
Featured NewsNovartis research shows technology talent increasingly drawn to pharma industry since COVID-19
Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today.
-
Media ReleaseNovartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges83% of technology (tech) professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago 86% of tech professionals agree: the…
-
In The NewsBreaking Through The Glass Ceiling - A Spring For Women In Artificial Intelligence
-
In The NewsThe Curious Advantage: Curiosity – The CEO and The Chief People and Organization Officer PerspectiveVas Narasimhan, CEO of Novartis and Steven Baert, Novartis’ Chief People and Organization Officer join the authors of The Curious Advantage Simon Brown, Paul Ashcroft and Garrick Jones, to…
-
Media ReleaseNovartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research effortsStudy discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19…
-
Streamlining systems to respond to COVID-19
Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.
-
Featured NewsWorld Sickle Cell Day 2020
Standing by people with sickle cell disease and their families
-
Media ReleaseNovartis expands Africa Sickle Cell Disease program to Uganda and TanzaniaNew collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care Program continues progress in Ghana with more than 2000 patients…
-
Key ReleaseNovartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritisFDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial…
-
Featured NewsDay of the African Child 2020
COVID-19 is disrupting Africa’s health services – potentially undermining decades of progress on child health.
Pagination
- ‹ Previous page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- …
- 150
- › Next page